---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-000840"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2022-02-08T23:59:59+00:00"
generated_at: "2026-06-27T10:24:55.298619+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# BioCryst appoints Machelle Sanders (NC Commerce Sec., ex-Biogen) to board

## Summary
- Appointed Machelle Sanders to board of directors effective Feb 8, 2022.
- Board size increased from 11 to 12; she will serve on Science Committee.
- Sanders is NC Secretary of Commerce and former Biogen operations exec with 30+ years pharma experience.
- She receives automatic grant of 26,667 stock options upon joining and annual 40,000 options.

## SEC filing metadata
- accession: 0001171843-22-000840
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2022-02-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184322000840/0001171843-22-000840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184322000840/f8k_020822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-000840
- JSON: https://secwatch.observer/filing/0001171843-22-000840.json
- Plain text: https://secwatch.observer/filing/0001171843-22-000840.txt

## Key facts
- Executive change
  Machelle Sanders was elected as Director at BIOCRYST PHARMACEUTICALS INC.
  - Action: elected
  - Role: Director
  source text: On February 4, 2022, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) voted to increase the size of the Board from 11 directors to 12 directors and elected Machelle Sanders to fill the vacancy created by the enlargement of the Board, effective February 8, 2022 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184322000840/0001171843-22-000840-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.